These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29398467)

  • 1. Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report.
    Yeruva SLH; Javadi MS; Stearns V
    Clin Breast Cancer; 2018 Jun; 18(3):e277-e280. PubMed ID: 29398467
    [No Abstract]   [Full Text] [Related]  

  • 2. Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).
    Lee J; Im SA; Kim GM; Jung KH; Kang SY; Park IH; Kim JH; Ahn HK; Park YH
    Cancer Res Treat; 2021 Jul; 53(3):695-702. PubMed ID: 33332933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative tumor board: recurrent breast cancer or new primary? Radiation oncology.
    Hirsch A
    Integr Cancer Ther; 2003 Sep; 2(3):272-6. PubMed ID: 15035891
    [No Abstract]   [Full Text] [Related]  

  • 4. Integrative tumor board: recurrent breast cancer or new primary? Case Presentation.
    Schmaltz J
    Integr Cancer Ther; 2003 Sep; 2(3):268-70. PubMed ID: 15035889
    [No Abstract]   [Full Text] [Related]  

  • 5. Ductal carcinoma in situ of the breast.
    Burstein HJ; Polyak K; Wong JS; Lester SC; Kaelin CM
    N Engl J Med; 2004 Apr; 350(14):1430-41. PubMed ID: 15070793
    [No Abstract]   [Full Text] [Related]  

  • 6. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
    Rugo HS; Finn RS; Gelmon K; Joy AA; Harbeck N; Castrellon A; Mukai H; Walshe JM; Mori A; Gauthier E; Lu DR; Bananis E; Martin M; Diéras V
    Clin Breast Cancer; 2020 Apr; 20(2):e173-e180. PubMed ID: 31836434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
    Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
    Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative tumor board: recurrent breast cancer or new primary? Naturopathic medicine.
    Fulop JA
    Integr Cancer Ther; 2003 Sep; 2(3):276-83. PubMed ID: 15035892
    [No Abstract]   [Full Text] [Related]  

  • 9. [Recurrence after treatment of breast intraductal carcinoma].
    Jourdain O; Tunon de Lara C; Quenel N; Stöckle E; Bussières E; Faucher A; Acharian V; Vilbas-Guegan C; de Mascarel I; Trojani M; Dilhuydy JM; Avril A
    J Gynecol Obstet Biol Reprod (Paris); 1998 Jun; 27(4):403-12. PubMed ID: 9690159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
    Gnant M; Dueck AC; Frantal S; Martin M; Burstein HJ; Greil R; Fox P; Wolff AC; Chan A; Winer EP; Pfeiler G; Miller KD; Colleoni M; Suga JM; Rubovsky G; Bliss JM; Mayer IA; Singer CF; Nowecki Z; Hahn O; Thomson J; Wolmark N; Amillano K; Rugo HS; Steger GG; Hernando Fernández de Aránguiz B; Haddad TC; Perelló A; Bellet M; Fohler H; Metzger Filho O; Jallitsch-Halper A; Solomon K; Schurmans C; Theall KP; Lu DR; Tenner K; Fesl C; DeMichele A; Mayer EL;
    J Clin Oncol; 2022 Jan; 40(3):282-293. PubMed ID: 34874182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative tumor board: recurrent breast cancer or new primary? Medical oncology.
    Boyd DB
    Integr Cancer Ther; 2003 Sep; 2(3):270-2. PubMed ID: 15035890
    [No Abstract]   [Full Text] [Related]  

  • 12. [Tumor recurrence in the salvaged breast; a second chance?].
    Roukema JA; Dolman A; Maat B
    Ned Tijdschr Geneeskd; 1989 Dec; 133(52):2593-5. PubMed ID: 2558321
    [No Abstract]   [Full Text] [Related]  

  • 13. Some clarity in the management of DCIS in breast cancer screening.
    Wald NJ
    J Med Screen; 2011; 18(3):112. PubMed ID: 22045817
    [No Abstract]   [Full Text] [Related]  

  • 14. Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer.
    Xi J; Oza A; Thomas S; Ademuyiwa F; Weilbaecher K; Suresh R; Bose R; Cherian M; Hernandez-Aya L; Frith A; Peterson L; Luo J; Krishnamurthy J; Ma CX
    J Natl Compr Canc Netw; 2019 Feb; 17(2):141-147. PubMed ID: 30787127
    [No Abstract]   [Full Text] [Related]  

  • 15. San Antonio Breast Cancer Symposium explores DCIS "battleground".
    Gottlieb N
    J Natl Cancer Inst; 2000 Feb; 92(4):295-7. PubMed ID: 10675372
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
    Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
    J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
    Kahan Z; Gil-Gil M; Ruiz-Borrego M; Carrasco E; Ciruelos E; Muñoz M; Bermejo B; Margeli M; Antón A; Casas M; Csöszi T; Murillo L; Morales S; Calvo L; Lang I; Alba E; de la Haba-Rodriguez J; Ramos M; López IÁ; Gal-Yam E; Garcia-Palomo A; Alvarez E; González-Santiago S; Rodríguez CA; Servitja S; Corsaro M; Rodrigálvarez G; Zielinski C; Martín M
    Eur J Cancer; 2021 Oct; 156():70-82. PubMed ID: 34425406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated radiation therapy for durable palliative treatment of bleeding, fungating breast cancers.
    Grewal AS; Freedman GM; Jones JA; Taunk NK
    Pract Radiat Oncol; 2019 Mar; 9(2):73-76. PubMed ID: 30665864
    [No Abstract]   [Full Text] [Related]  

  • 19. Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
    Wilkie J; Schickli MA; Berger MJ; Lustberg M; Reinbolt R; Noonan A; Ramaswamy B; Sardesai S; VanDeusen J; Wesolowski R; Williams N; Stover DG; Li J; Vargo CA
    Clin Breast Cancer; 2020 Feb; 20(1):33-40. PubMed ID: 31451366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is excision alone adequate treatment for low-risk ductal carcinoma-in-situ of the breast?
    Solin LJ
    J Clin Oncol; 2006 Mar; 24(7):1017-9. PubMed ID: 16461780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.